Abstract
Introduction The Cycle Threshold (CT) value in Real-time Polymerase Chain Reaction (RT-PCR) is where a target specific amplification signal becomes detectable and can infer viral load, risk of transmission and recovery in SARS-CoV-2 infections. Adoption into routine practice is however uncommon.
Gap Statement The lack of inclusion of CT values when reporting SARS-CoV-2 RT-PCR results in routine practice.
Aim To use CT values when reporting SARS-CoV-2 RT-PCR results in Qatar to aid clinical interpretation and patient management.
Methodology Routine CT values across 3 different RT-PCR platforms were reviewed for concordance at presentation and clearance in patients with COVID-19. An Indicative Threshold of CT 30 based on viral clearance kinetics categorized low and high CT values.
Results There was very high Correlation and Kappa Score agreement between the different gene targets in each platform (p<0.001). Using the Indicative Threshold it was possible to autoverify and add average CT values and append Interpretive Comments to all RT-PCR reports. The new reporting algorithm impacted immediately and safely on: physician interpretation of SARS-CoV-2 results; patient management; staff surveillance protocols; length of stay in quarantine; a redefinition of patient recovery.
Conclusion Incorporation of CT values into routine practice is possible across different RT-PCR platforms and adds useful information for patient management. The use of an Indicative Threshold and interpretive comments improves clinical interpretation of the result and could be a model for reporting other respiratory infections. The current accepted practice of withholding CT values should be reviewed by the profession, accreditation bodies and regulators.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approved by Hamad Medical Corporation Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
nalmolawi{at}hamad.qa
mkacem{at}hamad.qa
relkahlout2{at}hamad.qa
ealkuwari{at}hamad.qa
aalkhal{at}hamad.qa
igillani{at}hamad.qa
andrewjenko{at}hotmail.com
hsaeb{at}moph.gov.qa
malthani{at}moph.gov.qa
rbertollini{at}moph.gov.qa
hanan.arahim{at}qu.edu.qa
hsc2001{at}qatar-med.cornell.edu
ptang{at}sidra.org
alatif2{at}hamad.qa
saadalkaabi{at}hamad.qa
malmaslamanani{at}hamad.qa
bmorris{at}hamad.qa
nalansari2{at}hamad.qa
akaleeckal{at}hamad.qa
lja2002{at}qatar-med.cornell.edu
Conflict of Interest Authors have No Conflicts of Interest to declare.
Data Availability
All relevant data are available within the manuscript.